Emyria (ASX:EMD) Other Operating Expense: A$1.02 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Emyria Other Operating Expense?

Emyria ASX:EMD -2.50% Other Operating Expense is A$1.02 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Emyria's Other Operating Expense for the six months ended in Dec. 2025 was A$0.72 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.02 Mil.

Emyria's quarterly Other Operating Expense declined from Dec. 2024 (A$0.94 Mil) to Jun. 2025 (A$0.30 Mil) but then increased from Jun. 2025 (A$0.30 Mil) to Dec. 2025 (A$0.72 Mil).

Emyria's annual Other Operating Expense declined from Jun. 2023 (A$1.25 Mil) to Jun. 2024 (A$1.22 Mil) but then increased from Jun. 2024 (A$1.22 Mil) to Jun. 2025 (A$1.24 Mil).

Emyria Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Emyria's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emyria Other Operating Expense Chart

Emyria Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Operating Expense
Get a 7-Day Free Trial 0.86 1.20 1.25 1.22 1.24

Emyria Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.52 0.94 0.30 0.72

Emyria Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of A$1.02 Mil mean?
Emyria (ASX:EMD) has a Other Operating Expense of A$1.02 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Emyria and its competitors.
Is Emyria's Other Operating Expense too high?
Emyria's current Other Operating Expense is A$1.02 Mil.
How does Emyria's Other Operating Expense compare to VEEV and BTSG?
Emyria's Other Operating Expense of A$1.02 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Healthcare Providers & Services company?
A good Other Operating Expense depends on the Healthcare Providers & Services industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Emyria and its competitors. Emyria's current Other Operating Expense is A$1.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.04 — trading 30% above its estimated fair value. The current Other Operating Expense is A$1.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Emyria (ASX:EMD), the current Other Operating Expense is A$1.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emyria Business Description

Other Exchanges Q84:Germany
Address D2, 661 Newcastle Street, PO Box 1442, Leederville, WA, AUS, 6007
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.